



<b>UHID</b>	<b>12768008</b>	<b>Date</b>	<b>14/10/2023</b>		
<b>Name</b>	<b>MRS. Sonali Gejage</b>	<b>Sex</b>	<b>F</b>	<b>Age</b>	<b>26</b>
<b>OPD</b>	<b>Ophthal</b>	<b>Health Check Up</b>			

Drug allergy:  
 Sys illness:

Vn 6/6  
16/6.

o/s :: A/S J WAK

Indlu  
exam J WAK

Exp.

- opd Agaluke / opd  
 (B66) Refresh  
Jeans  
 1-1-1  
 x/mth

*[Handwritten signature]*

**PATIENT NAME : MRS.SONALI GANESH GEJAGE**

**REF. DOCTOR :**

**CODE/NAME & ADDRESS : C000045507**  
 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

**ACCESSION NO : 0022WJ002975**  
 PATIENT ID : FH.12768008  
 CLIENT PATIENT ID: UID:12768008  
 ABHA NO :

AGE/SEX : 26 Years Female  
 DRAWN : 14/10/2023 10:45:00  
 RECEIVED : 14/10/2023 10:46:32  
 REPORTED : 14/10/2023 13:47:17

**CLINICAL INFORMATION :**

UID:12768008 REQNO-1594572  
 CORP-OPD  
 BILLNO-1501230PCR059036  
 BILLNO-1501230PCR059036

Test Report Status	Results	Biological Reference Interval	Units
Final			

**HAEMATOLOGY - CBC**

**CBC-5, EDTA WHOLE BLOOD**

**BLOOD COUNTS, EDTA WHOLE BLOOD**

HEMOGLOBIN (HB)	12.3	12.0 - 15.0	g/dL
METHOD : SLS METHOD			
RED BLOOD CELL (RBC) COUNT	4.63	3.8 - 4.8	mil/ $\mu$ L
METHOD : HYDRODYNAMIC FOCUSING			
WHITE BLOOD CELL (WBC) COUNT	7.31	4.0 - 10.0	thou/ $\mu$ L
METHOD : FLUORESCENCE FLOW CYTOMETRY			
PLATELET COUNT	292	150 - 410	thou/ $\mu$ L
METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION			

**RBC AND PLATELET INDICES**

HEMATOCRIT (PCV)	39.8	36.0 - 46.0	%
METHOD : CUMULATIVE PULSE HEIGHT DETECTION METHOD			
MEAN CORPUSCULAR VOLUME (MCV)	86.0	83.0 - 101.0	fL
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	26.6 Low	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC)	30.9 Low	31.5 - 34.5	g/dL
METHOD : CALCULATED PARAMETER			
RED CELL DISTRIBUTION WIDTH (RDW)	13.4	11.6 - 14.0	%
METHOD : CALCULATED PARAMETER			
MENTZER INDEX	18.6		
METHOD : CALCULATED PARAMETER			
MEAN PLATELET VOLUME (MPV)	8.7	6.8 - 10.9	fL
METHOD : CALCULATED PARAMETER			

**WBC DIFFERENTIAL COUNT**

**Dr. Akshay Dhotre, MD**  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist



View Details



View Report

**PERFORMED AT :**

Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222, 022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -



Patient Ref. No. 22000000878681

**PATIENT NAME : MRS.SONALI GANESH GEJAGE**
**REF. DOCTOR :**
**CODE/NAME & ADDRESS : C000045507**

 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

**ACCESSION NO : 0022WJ002975**

PATIENT ID : FH.12768008

CLIENT PATIENT ID: UID:12768008

ABHA NO :

AGE/SEX : 26 Years Female

DRAWN : 14/10/2023 10:45:00

RECEIVED : 14/10/2023 10:46:32

REPORTED : 14/10/2023 13:47:17

**CLINICAL INFORMATION :**

UID:12768008 REQNO-1594572

CORP-OPD

BILLNO-1501230PCR059036

BILLNO-1501230PCR059036

Test Report Status	Final	Results	Biological Reference Interval	Units
NEUTROPHILS		62	40.0 - 80.0	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
LYMPHOCYTES		30	20.0 - 40.0	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
MONOCYTES		6	2.0 - 10.0	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
EOSINOPHILS		2	1 - 6	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
BASOPHILS		0	0 - 2	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
ABSOLUTE NEUTROPHIL COUNT		4.53	2.0 - 7.0	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE LYMPHOCYTE COUNT		2.19	1.0 - 3.0	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT		0.44	0.2 - 1.0	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT		0.15	0.02 - 0.50	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT		0 Low	0.02 - 0.10	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
NEUTROPHIL LYMPHOCYTE RATIO (NLR)		2.0		
METHOD : CALCULATED				

**MORPHOLOGY**
**RBC**

METHOD : MICROSCOPIC EXAMINATION

**WBC**

METHOD : MICROSCOPIC EXAMINATION

**PLATELETS**

METHOD : MICROSCOPIC EXAMINATION

PREDOMINANTLY NORMOCYTIC NORMOCHROMIC

NORMAL MORPHOLOGY

ADEQUATE


**Dr. Akshay Dhotre, MD**  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist


View Details



View Report

**PERFORMED AT :**

 Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222, 022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -


Patient Ref. No. 22000000878681



**PATIENT NAME : MRS.SONALI GANESH GEJAGE**
**REF. DOCTOR :**
**CODE/NAME & ADDRESS : C000045507**

 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

**ACCESSION NO : 0022WJ002975**
**PATIENT ID : FH.12768008**
**CLIENT PATIENT ID: UID:12768008**
**ABHA NO :**
**AGE/SEX : 26 Years Female**
**DRAWN : 14/10/2023 10:45:00**
**RECEIVED : 14/10/2023 10:46:32**
**REPORTED : 14/10/2023 13:47:17**
**CLINICAL INFORMATION :**

UID:12768008 REQNO-1594572

CORP-OPD

BILLNO-150123OPCR059036

BILLNO-150123OPCR059036

**Test Report Status**
**Final**
**Results**
**Biological Reference Interval**
**Units**
**Interpretation(s)**

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504)

This ratio element is a calculated parameter and out of NABL scope.



**Dr. Akshay Dhotre, MD**  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist

Page 3 Of 1



View Details



View Report

**PERFORMED AT :**

Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222,022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -



Patient Ref. No. 22000000878681

**PATIENT NAME : MRS.SONALI GANESH GEJAGE**

**REF. DOCTOR :**

**CODE/NAME & ADDRESS : C000045507**  
 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

**ACCESSION NO : 0022WJ002975**  
 PATIENT ID : FH.12768008  
 CLIENT PATIENT ID: UID:12768008  
 ABHA NO :

**AGE/SEX : 26 Years Female**  
**DRAWN : 14/10/2023 10:45:00**  
**RECEIVED : 14/10/2023 10:46:32**  
**REPORTED : 14/10/2023 13:47:17**

**CLINICAL INFORMATION :**

UID:12768008 REQNO-1594572  
 CORP-OPD  
 BILLNO-150123OPCR059036  
 BILLNO-150123OPCR059036

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**HAEMATOLOGY**

**ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD**

E.S.R	23 High	0 - 20	mm at 1 hr
METHOD : WESTERGREN METHOD			

**GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD**

HBA1C	6.1 High	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
METHOD : HB VARIANT (HPLC)			
ESTIMATED AVERAGE GLUCOSE(EAG)	128.4 High	< 116.0	mg/dL
METHOD : CALCULATED PARAMETER			

**Interpretation(s)**

**ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD-TEST DESCRIPTION :-**  
 Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

**TEST INTERPRETATION**

**Increase in:** Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.  
 Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).  
 In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.  
**Decreased in:** Polycythemia vera, Sickle cell anemia

**LIMITATIONS**

**False elevated ESR :** Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia  
**False Decreased :** Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

**Dr. Akshay Dhotre, MD**  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist



View Details



View Report

**PERFORMED AT :**

Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222,022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -



**PATIENT NAME : MRS.SONALI GANESH GEJAGE**
**REF. DOCTOR :**
**CODE/NAME & ADDRESS : C000045507**

 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

**ACCESSION NO : 0022WJ002975**

PATIENT ID : FH.12768008

CLIENT PATIENT ID: UID:12768008

ABHA NO :

AGE/SEX : 26 Years Female

DRAWN : 14/10/2023 10:45:00

RECEIVED : 14/10/2023 10:46:32

REPORTED : 14/10/2023 13:47:17

**CLINICAL INFORMATION :**

 UID:12768008 REQNO-1594572  
 CORP-OPD  
 BILLNO-150123OPCR059036  
 BILLNO-150123OPCR059036

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**REFERENCE :**

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- Evaluating the long-term control of blood glucose concentrations in diabetic patients.
  - Diagnosing diabetes.
  - Identifying patients at increased risk for diabetes (prediabetes).
- The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.
- eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.
  - eAG gives an evaluation of blood glucose levels for the last couple of months.
  - eAG is calculated as  $eAG (mg/dl) = 28.7 * HbA1c - 46.7$

**HbA1c Estimation can get affected due to :**

- Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- Vitamin C & E are reported to falsely lower test results (possibly by inhibiting glycation of hemoglobin).
- Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.
- Interference of hemoglobinopathies in HbA1c estimation is seen in
  - Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
  - Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
  - HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy



**Dr. Akshay Dhotre, MD**  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist

Page 5 Of 16



View Details



View Report

**PERFORMED AT :**

 Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222, 022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -


Patient Ref. No. 2200000878681



**PATIENT NAME : MRS.SONALI GANESH GEJAGE**
**REF. DOCTOR :**
**CODE/NAME & ADDRESS : C000045507**

 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

**ACCESSION NO : 0022WJ002975**

PATIENT ID : FH.12768008

CLIENT PATIENT ID: UID:12768008

ABHA NO :

AGE/SEX : 26 Years Female

DRAWN : 14/10/2023 10:45:00

RECEIVED : 14/10/2023 10:46:32

REPORTED : 14/10/2023 13:47:17

**CLINICAL INFORMATION :**

 UID:12768008 REQNO-1594572  
 CORP-OPD  
 BILLNO-150123OPCR059036  
 BILLNO-150123OPCR059036

Test Report Status	Results	Biological Reference Interval	Units
Final			

**IMMUNOHAEMATOLOGY**
**ABO GROUP & RH TYPE, EDTA WHOLE BLOOD**

ABO GROUP	TYPE B
METHOD : TUBE AGGLUTINATION	
RH TYPE	POSITIVE
METHOD : TUBE AGGLUTINATION	

**Interpretation(s)**

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.



**Dr. Akshay Dhotre, MD**  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist

Page 6 Of 16



View Details



View Report

**PERFORMED AT :**

 Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222,022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -


Patient Ref. No. 22000000878681

<b>PATIENT NAME :</b> MRS.SONALI GANESH GEJAGE	<b>REF. DOCTOR :</b>
<b>CODE/NAME &amp; ADDRESS :</b> C000045507 FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001	<b>AGE/SEX :</b> 26 Years Female <b>DRAWN :</b> 14/10/2023 10:45:00 <b>RECEIVED :</b> 14/10/2023 10:46:32 <b>REPORTED :</b> 14/10/2023 13:47:17
<b>ACCESSION NO :</b> 0022WJ002975	
<b>PATIENT ID :</b> FH.12768008	
<b>CLIENT PATIENT ID: UID:</b> 12768008	
<b>ABHA NO :</b>	

**CLINICAL INFORMATION :**

UID:12768008 REQNO-1594572  
CORP-OPD  
BILLNO-150123OPCR059036  
BILLNO-150123OPCR059036

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**BIOCHEMISTRY****LIVER FUNCTION PROFILE, SERUM**

BILIRUBIN, TOTAL	0.63	0.2 - 1.0	mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, DIRECT	0.12	0.0 - 0.2	mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, INDIRECT	0.51	0.1 - 1.0	mg/dL
METHOD : CALCULATED PARAMETER			
TOTAL PROTEIN	7.6	6.4 - 8.2	g/dL
METHOD : BIURET			
ALBUMIN	3.8	3.4 - 5.0	g/dL
METHOD : BCP DYE BINDING			
GLOBULIN	3.8	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.0	1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	11 <b>Low</b>	15 - 37	U/L
METHOD : UV WITH PSP			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	14	< 34.0	U/L
METHOD : UV WITH PSP			
ALKALINE PHOSPHATASE	95	30 - 120	U/L
METHOD : PNPP-ANP			
GAMMA GLUTAMYL TRANSFERASE (GGT)	19	5 - 55	U/L
METHOD : GAMMA GLUTAMYL CARBOXY 4-NITROANILIDE			
LACTATE DEHYDROGENASE	150	81 - 234	U/L
METHOD : LACTATE -PYRUVATE			

**GLUCOSE FASTING, FLUORIDE PLASMA**

FBS (FASTING BLOOD SUGAR)	96	Normal : < 100 Pre-diabetes: 100-125 Diabetes: >=126	mg/dL
---------------------------	----	--	-------

METHOD : HEXOKINASE



Dr. Akshay Dhotre, MD  
(Reg, no. MMC 2019/09/6377)  
Consultant Pathologist




View Details



View R

**PERFORMED AT :**

Agilus Diagnostics Ltd.  
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
Navi Mumbai, 400703  
Maharashtra, India  
Tel : 022-39199222, 022-49723322,  
CIN - U74899PB1995PLC045956  
Email : -



Patient Ref. No. 220000008786



**PATIENT NAME : MRS.SONALI GANESH GEJAGE**
**REF. DOCTOR :**
**CODE/NAME & ADDRESS : C000045507**

 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

**ACCESSION NO : 0022WJ002975**

PATIENT ID : FH.12768008

CLIENT PATIENT ID: UID:12768008

ABHA NO :

AGE/SEX : 26 Years Female

DRAWN : 14/10/2023 10:45:00

RECEIVED : 14/10/2023 10:46:32

REPORTED : 14/10/2023 13:47:17

**CLINICAL INFORMATION :**

 UID:12768008 REQNO-1594572  
 CORP-OPD  
 BILLNO-150123OPCR059036  
 BILLNO-150123OPCR059036

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**KIDNEY PANEL - 1**
**BLOOD UREA NITROGEN (BUN), SERUM**

BLOOD UREA NITROGEN	7	6 - 20	mg/dL
METHOD : UREASE - UV			

**CREATININE EGFR- EPI**

CREATININE	0.67	0.60 - 1.10	mg/dL
METHOD : ALKALINE PICRATE KINETIC JAFFES			
AGE	26		years
GLOMERULAR FILTRATION RATE (FEMALE)	123.55	Refer Interpretation Below	mL/min/1.73m <sup>2</sup>
METHOD : CALCULATED PARAMETER			

**BUN/CREAT RATIO**

BUN/CREAT RATIO	10.45	5.00 - 15.00	
METHOD : CALCULATED PARAMETER			

**URIC ACID, SERUM**

URIC ACID	4.4	2.6 - 6.0	mg/dL
METHOD : URICASE UV			

**TOTAL PROTEIN, SERUM**

TOTAL PROTEIN	7.6	6.4 - 8.2	g/dL
METHOD : BIURET			



Dr. Akshay Dhotre, MD  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist

Page 8 Of 16



View Details



View Report

**PERFORMED AT :**

 Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222, 022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -


Patient Ref. No. 22000000878681

**PATIENT NAME : MRS.SONALI GANESH GEJAGE**
**REF. DOCTOR :**
**CODE/NAME & ADDRESS : C000045507**  
 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

**ACCESSION NO : 0022WJ002975**  
**PATIENT ID : FH.12768008**  
**CLIENT PATIENT ID: UID:12768008**  
**ABHA NO :**
**AGE/SEX : 26 Years Female**  
**DRAWN : 14/10/2023 10:45:00**  
**RECEIVED : 14/10/2023 10:46:32**  
**REPORTED : 14/10/2023 13:47:17**
**CLINICAL INFORMATION :**

 UID:12768008 REQNO-1594572  
 CORP-OPD  
 BILLNO-150123OPCR059036  
 BILLNO-150123OPCR059036

Test Report Status	Final	Results	Biological Reference Interval	Units
<b>ALBUMIN, SERUM</b>				
ALBUMIN		3.8	3.4 - 5.0	g/dL
METHOD : BCP DYE BINDING				
<b>GLOBULIN</b>				
GLOBULIN		3.8	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER				
<b>ELECTROLYTES (NA/K/CL), SERUM</b>				
SODIUM, SERUM		136	136 - 145	mmol/L
METHOD : ISE INDIRECT				
POTASSIUM, SERUM		4.09	3.50 - 5.10	mmol/L
METHOD : ISE INDIRECT				
CHLORIDE, SERUM		101	98 - 107	mmol/L
METHOD : ISE INDIRECT				

**Interpretation(s)**
**Interpretation(s)**
**LIVER FUNCTION PROFILE, SERUM-**

**Bilirubin** is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease. Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.


**Dr. Akshay Dhotre, MD**  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist


View Details



View Report

**PERFORMED AT :**

 Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222, 022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -


Patient Ref. No. 2200000878681



**PATIENT NAME : MRS.SONALI GANESH GEJAGE**

**REF. DOCTOR :**

**CODE/NAME & ADDRESS : C000045507**  
 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

**ACCESSION NO : 0022WJ002975**  
**PATIENT ID : FH.12768008**  
**CLIENT PATIENT ID: UID:12768008**  
**ABHA NO :**

**AGE/SEX : 26 Years Female**  
**DRAWN : 14/10/2023 10:45:00**  
**RECEIVED : 14/10/2023 10:46:32**  
**REPORTED : 14/10/2023 13:47:17**

**CLINICAL INFORMATION :**

UID:12768008 REQNO-1594572  
 CORP-OPD  
 BILLNO-1501230PCR059036  
 BILLNO-1501230PCR059036

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**AST** is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

**ALP** is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

**GGT** is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

**Total Protein** also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

**Albumin** is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

**GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

**Increased in:** Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

**Decreased in :** Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g. galactosemia), Drugs-insulin, ethanol, propranolol, sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

**NOTE:** While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

**BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels** include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

**Causes of decreased level** include Liver disease, SIADH.

- **CREATININE EGFR- EPI--** Kidney disease outcomes quality initiative (KDIGO) guidelines state that estimation of GFR is the best overall indices of the Kidney function. Reduction in GFR implies progression of underlying disease.
- It gives a rough measure of number of functioning nephrons.
- The GFR is a calculation based on serum creatinine test.
- Creatinine is mainly derived from the metabolism of creatine in muscle, and its generation is proportional to the total muscle mass. As a result, mean creatinine generation is higher in men than in women, in younger than in older individuals, and in blacks than in whites.
- Creatinine is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate.
- When kidney function is compromised, excretion of creatinine decreases with a consequent increase in blood creatinine levels. With the creatinine test, a reasonable estimate of the actual GFR can be determined.
- This equation takes into account several factors that impact creatinine production, including age, gender, and race.
- CKD EPI (Chronic kidney disease epidemiology collaboration) equation performed better than MDRD equation especially when GFR is high (>60 ml/min per 1.73m2).. This formula has less bias and greater accuracy which helps in early diagnosis and also reduces the rate of false positive diagnosis of CKD.

**References:**

National Kidney Foundation (NKF) and the American Society of Nephrology (ASN).  
 Estimated GFR Calculated Using the CKD-EPI equation-<https://testguide.labmed.uw.edu/guideline/egfr>  
 Ghuman JK, et al. Impact of Removing Race Variable on CKD Classification Using the Creatinine-Based 2021 CKD-EPI Equation. Kidney Med 2022, 4:100471. 35756325  
 Harrison's Principle of Internal Medicine, 21st ed. pg 62 and 334  
**URIC ACID, SERUM-Causes of Increased levels:**-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM, Metabolic syndrome  
**Causes of decreased levels:**-Low Zinc intake,OCP, Multiple Sclerosis  
**TOTAL PROTEIN, SERUM-**is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.  
**Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

**Dr. Akshay Dhotre, MD**  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist



View Details



View Report

**PERFORMED AT :**

Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222,022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -



Patient Ref. No. 2200000878681



**PATIENT NAME : MRS.SONALI GANESH GEJAGE**
**REF. DOCTOR :**
**CODE/NAME & ADDRESS : C000045507**

 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

**ACCESSION NO : 0022WJ002975**

PATIENT ID : FH.12768008

CLIENT PATIENT ID: UID:12768008

ABHA NO :

AGE/SEX : 26 Years Female

DRAWN : 14/10/2023 10:45:00

RECEIVED : 14/10/2023 10:46:32

REPORTED : 14/10/2023 13:47:17

**CLINICAL INFORMATION :**

UID:12768008 REQNO-1594572

CORP-OPD

BILLNO-150123OPCR059036

BILLNO-150123OPCR059036

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**Lower-than-normal levels may be due to:** Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.  
**ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:** Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.



**Dr. Akshay Dhotre, MD**  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist

Page 11 Of 11



View Details



View Report

**PERFORMED AT :**

Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222, 022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -



Patient Ref. No. 22000000878681

**PATIENT NAME : MRS.SONALI GANESH GEJAGE**
**REF. DOCTOR :**
**CODE/NAME & ADDRESS : C000045507**

 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

**ACCESSION NO : 0022WJ002975**

PATIENT ID : FH.12768008

CLIENT PATIENT ID: UID:12768008

ABHA NO :

AGE/SEX : 26 Years Female

DRAWN : 14/10/2023 10:45:00

RECEIVED : 14/10/2023 10:46:32

REPORTED : 14/10/2023 13:47:17

**CLINICAL INFORMATION :**

 UID:12768008 REQNO-1594572  
 CORP-OPD  
 BILLNO-150123OPCR059036  
 BILLNO-150123OPCR059036

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**BIOCHEMISTRY - LIPID**
**LIPID PROFILE, SERUM**

CHOLESTEROL, TOTAL	155	< 200 Desirable 200 - 239 Borderline High >= 240 High	mg/dL
METHOD : ENZYMATIC/COLORIMETRIC, CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE			
TRIGLYCERIDES	148	< 150 Normal 150 - 199 Borderline High 200 - 499 High >=500 Very High	mg/dL
METHOD : ENZYMATIC ASSAY			
HDL CHOLESTEROL	36 <b>Low</b>	< 40 Low >=60 High	mg/dL
METHOD : DIRECT MEASURE - PEG			
LDL CHOLESTEROL, DIRECT	100	< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High >= 190 Very High	mg/dL
METHOD : DIRECT MEASURE WITHOUT SAMPLE PRETREATMENT			
NON HDL CHOLESTEROL	119	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
METHOD : CALCULATED PARAMETER			
VERY LOW DENSITY LIPOPROTEIN	29.6	</= 30.0	mg/dL
METHOD : CALCULATED PARAMETER			
CHOL/HDL RATIO	4.3	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
METHOD : CALCULATED PARAMETER			


**Dr. Akshay Dhotre, MD**  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist

Page 12 Of 11



View Details



View Report

**PERFORMED AT :**

 Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222, 022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -


Patient Ref. No. 22000000878681

**PATIENT NAME : MRS.SONALI GANESH GEJAGE**
**REF. DOCTOR :**
**CODE/NAME & ADDRESS : C000045507**

 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

**ACCESSION NO : 0022WJ002975**

 PATIENT ID : FH.12768008  
 CLIENT PATIENT ID: UID:12768008  
 ABHA NO :

AGE/SEX : 26 Years Female

DRAWN : 14/10/2023 10:45:00

RECEIVED : 14/10/2023 10:46:32

REPORTED : 14/10/2023 13:47:17

**CLINICAL INFORMATION :**

 UID:12768008 REQNO-1594572  
 CORP-OPD  
 BILLNO-150123OPCR059036  
 BILLNO-150123OPCR059036

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

LDL/HDL RATIO

2.8

 0.5 - 3.0 Desirable/Low Risk  
 3.1 - 6.0 Borderline/Moderate  
 Risk  
 >6.0 High Risk

METHOD : CALCULATED PARAMETER

**Interpretation(s)**

**Dr. Akshay Dhotre, MD**  
 (Reg,no. MMC 2019/09/6377)  
 Consultant Pathologist

Page 13 Of 16



View Details



View Report

**PERFORMED AT :**

 Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222,022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -


Patient Ref. No. 22000000878681



PATIENT NAME : MRS.SONALI GANESH GEJAGE		REF. DOCTOR :
CODE/NAME & ADDRESS : C000045507	ACCESSION NO : 0022WJ002975	AGE/SEX : 26 Years Female
FORTIS VASHI-CHC -SPLZD	PATIENT ID : FH.12768008	DRAWN : 14/10/2023 10:45:00
FORTIS HOSPITAL # VASHI,	CLIENT PATIENT ID: UID:12768008	RECEIVED : 14/10/2023 10:46:32
MUMBAI 440001	ABHA NO :	REPORTED : 14/10/2023 13:47:17

## CLINICAL INFORMATION :

UID:12768008 REQNO-1594572  
CORP-OPD  
BILLNO-150123OPCR059036  
BILLNO-150123OPCR059036

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## CLINICAL PATH - URINALYSIS

## URINALYSIS

## PHYSICAL EXAMINATION, URINE

COLOR	PALE YELLOW
METHOD : PHYSICAL	
APPEARANCE	SLIGHTLY HAZY
METHOD : VISUAL	

## CHEMICAL EXAMINATION, URINE

PH	6.0	4.7 - 7.5
METHOD : REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD		
SPECIFIC GRAVITY	<=1.005	1.003 - 1.035
METHOD : REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)		
PROTEIN	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE		
GLUCOSE	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD		
KETONES	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE		
BLOOD	DETECTED (+)	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN		
BILIRUBIN	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT		
UROBILINOGEN	NORMAL	NORMAL
METHOD : REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRlich REACTION)		
NITRITE	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE		
LEUKOCYTE ESTERASE	DETECTED (++)	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, ESTERASE HYDROLYSIS ACTIVITY		



Dr. Akshay Dhotre, MD  
(Reg.no. MMC 2019/09/6377)  
Consultant Pathologist



Dr. Rekha Nair, MD  
(Reg No. MMC 2001/06/2354)  
Microbiologist



View Details



View Report

## PERFORMED AT :

Agilus Diagnostics Ltd.  
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
Navi Mumbai, 400703  
Maharashtra, India  
Tel : 022-39199222,022-49723322,  
CIN - U74899PB1995PLC045956  
Email : -



Patient Ref. No. 2200000878681


<b>PATIENT NAME :</b> MRS.SONALI GANESH GEJAGE	<b>REF. DOCTOR :</b>	
<b>CODE/NAME &amp; ADDRESS :</b> C000045507 FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001	<b>ACCESSION NO :</b> 0022WJ002975 <b>PATIENT ID :</b> FH.12768008 <b>CLIENT PATIENT ID:</b> UID:12768008 <b>ABHA NO :</b>	<b>AGE/SEX :</b> 26 Years Female <b>DRAWN :</b> 14/10/2023 10:45:00 <b>RECEIVED :</b> 14/10/2023 10:46:32 <b>REPORTED :</b> 14/10/2023 13:47:17


**CLINICAL INFORMATION :**

UID:12768008 REQNO-1594572  
CORP-OPD  
BILLNO-150123OPCR059036  
BILLNO-150123OPCR059036

Test Report Status	Final	Results	Biological Reference Interval	Units
<b>MICROSCOPIC EXAMINATION, URINE</b>				
RED BLOOD CELLS		2 - 3	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION				
PUS CELL (WBC'S)		30-40	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION				
EPITHELIAL CELLS		10-15	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION				
CASTS		NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
CRYSTALS		NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
BACTERIA		DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION				
YEAST		NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION				
REMARKS		URINARY MICROSCOPIC EXAMINATION DONE ON URINARY CENTRIFUGED SEDIMENT.		

**Interpretation(s)**

  
**Dr. Akshay Dhotre, MD**  
(Reg.no. MMC 2019/09/6377)  
Consultant Pathologist

  
**Dr. Rekha Nair, MD**  
(Reg No. MMC 2001/06/2354)  
Microbiologist



View Details



View Report

**PERFORMED AT :**

Agilus Diagnostics Ltd.  
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
Navi Mumbai, 400703  
Maharashtra, India  
Tel : 022-39199222, 022-49723322,  
CIN - U74899PB1995PLC045956  
Email : -



Patient Ref. No. 2200000087868

**PATIENT NAME : MRS.SONALI GANESH GEJAGE**

**REF. DOCTOR :**

**CODE/NAME & ADDRESS : C000045507**  
 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

**ACCESSION NO : 0022WJ002975**  
 PATIENT ID : FH.12768008  
 CLIENT PATIENT ID: UID:12768008  
 ABHA NO :

AGE/SEX : 26 Years Female  
 DRAWN : 14/10/2023 10:45:00  
 RECEIVED : 14/10/2023 10:46:32  
 REPORTED : 14/10/2023 13:47:17

**CLINICAL INFORMATION :**

UJD:12768008 REQNO-1594572  
 CORP-OPD  
 BILLNO-150123OPCR059036  
 BILLNO-150123OPCR059036

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**SPECIALISED CHEMISTRY - HORMONE**

**THYROID PANEL, SERUM**

T3	109.4	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester: 105.0 - 230.0 2nd Trimester: 129.0 - 262.0 3rd Trimester: 135.0 - 262.0	ng/dL
METHOD : ELECTROCHEMILUMINESCENCE IMMUNOASSAY, COMPETITIVE PRINCIPLE			
T4	6.89	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70	µg/dL
METHOD : ELECTROCHEMILUMINESCENCE IMMUNOASSAY, COMPETITIVE PRINCIPLE			
TSH (ULTRASENSITIVE)	1.110	Non Pregnant Women 0.27 - 4.20 Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15	µIU/mL
METHOD : ELECTROCHEMILUMINESCENCE,SANDWICH IMMUNOASSAY			

**Interpretation(s)**

**\*\*End Of Report\*\***

Please visit [www.agilusdiagnostics.com](http://www.agilusdiagnostics.com) for related Test Information for this accession

**Dr. Akshay Dhotre, MD**  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist



View Details



View Report

**PERFORMED AT :**

Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222,022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -





10/14/2023 2:26:52 PM

SONALI GEJAGE  
Female

12768008  
26 Years

HC

Normal

.....normal P axis, V-rate 50-99

Rate 68 Sinus rhythm.  
PR 167 Baseline wander in lead(s) I, III, aVR, aVL, V2  
QRSD 72  
QT 379  
QTc 404


--AXIS--

P 70  
QRS 71  
T 41

- NORMAL ECG -

Unconfirmed Diagnosis

12 Lead; Standard Placement



F 50 ~ 0.50-100 Hz W

100B CL P?

Speed: 25 mm/sec Limb: 10 mm/mV Chest: 10.0 mm/mV

Device:

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220

Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823

GST IN : 27AABCH5894D1ZG

PAN NO : AABCH5894D



Hiranandani  
HOSPITAL  
(A Fortis Network Hospital)

Date: 14/Oct/2023

DEPARTMENT OF RADIOLOGY

Name: Mrs. Sonali Ganesh Gejage

Age | Sex: 26 YEAR(S) | Female

Order Station : FO-OPD

Bed Name :

UHID | Episode No : 12768008 | 59810/23/1501

Order No | Order Date: 1501/PN/OP/2310/124591 | 14-Oct-2023

Admitted On | Reporting Date : 14-Oct-2023 13:00:09

Order Doctor Name : Dr.SELF.

X-RAY-CHEST- PA

**Findings:**

Both lung fields are clear.

The cardiac shadow appears within normal limits.

Trachea and major bronchi appears normal.

Both costophrenic angles are well maintained.

Bony thorax is unremarkable.

**DR. YOGINI SHAH**  
DMRD., DNB. (Radiologist)





(For Billing/Reports & Discharge Summary only)

Patient Name	: Sonali Ganesh Gejage	Patient ID	: 12768008
Sex / Age	: F / 26Y 1M 7D	Accession No.	: PHC.6766503
Modality	: US	Scan DateTime	: 14-10-2023 12:38:19
IPID No	: 59810/23/1501	ReportDatetime	: 14-10-2023 12:51:07

### USG – WHOLE ABDOMEN

**LIVER** is mildly enlarged in size (16.6 cm) and normal in echogenicity. No IHBR dilatation. No focal lesion is seen in liver. Portal vein appears normal in caliber.

**GALL BLADDER** is physiologically distended and shows multiple calculi within the lumen, largest measuring 20 mm. Gall bladder reveals normal wall thickness. No evidence of pericholecystic collection. **CBD** appears normal in caliber.

**SPLEEN** is normal in size and echogenicity.

**BOTH KIDNEYS** are normal in size and echogenicity. The central sinus complex is normal. No evidence of calculi/hydronephrosis.

Right kidney measures 11.5 x 3.8 cm.

Left kidney measures 12.0 x 5.0 cm.

**PANCREAS** is normal in size and morphology. No evidence of peripancreatic collection.

**URINARY BLADDER** is normal in capacity and contour. Bladder wall is normal in thickness. No evidence of intravesical calculi.

**UTERUS** is normal in size, measuring 7.6 x 5.1 x 3.3 cm.

Endometrium measures 5.9 mm in thickness.

Right ovary is normal and measures 3.7 x 1.8 x 2.5 cm, volume 9.0 cc.

Left ovary is bulky and measures 3.4 x 4.1 x 2.6 cm, volume 19.8 cc. Two dominant follicles, measuring 17 x 16 mm & 16 x 10 mm are noted within.

No evidence of ascites.

### Impression:

- Mild hepatomegaly.
- Cholelithiasis without changes of cholecystitis.
- Bulky left ovary with two dominant follicles within.

DR. CHETAN KHADKE

M.D. (Radiologist)